Revolution Medicines (RVMD) Stock Soars 20% on Breakthrough Pancreatic Cancer Trial Results

Table of Contents Revolution Medicines (RVMD) stock experienced a dramatic 20% surge in Sunday overnight trading and continued climbing 7.3% to $169 in Monday’s premarket session following the release of what industry experts are describing as “groundbreaking” data for its investigational pancreatic cancer medication, daraxonrasib. Revolution Medicines, Inc., RVMD The clinical data emerged from the Phase 3 RASolute 302 trial, which was featured during the ASCO Plenary Session and simultaneously released in The New England Journal of Medicine. Patients treated with daraxonrasib achieved a median overall survival of 13.2 months—essentially doubling the 6.7-month median observed in those receiving conventional chemotherapy. This milestone represents the first time any Phase 3 clinical trial has demonstrated median survival exceeding 12 months for previously treated metastatic pancreatic cancer. The international study enrolled 500 participants and evaluated the once-daily oral medication against standard-of-care chemotherapy in patients who had previously undergone at least one prior treatment regimen. Beyond survival extension, daraxonrasib demonstrated a 60% reduction in mortality risk and significantly delayed disease progression. Patients maintained stable disease for a median of 7.2 months before experiencing cancer advancement, compared to only 3.6 months in the chemotherapy group. Tumor response rates reached 32% among daraxonrasib recipients, substantially higher than the 11% response rate seen with chemotherapy. Notably, these benefits were consistent across patient populations regardless of whether they carried detectable RAS mutations. Beyond extending life, patients receiving daraxonrasib maintained adequate cancer-related pain control for a median of 9.2 months, significantly longer than the 3.8 months observed with chemotherapy. Quality of life metrics remained stable for 5.7 months versus 2.6 months in the control arm. The safety profile proved equally impressive. Only 1.2% of daraxonrasib-treated patients discontinued therapy due to adverse events, dramatically lower than the 11.2% discontinuation rate in the chemotherapy group. Raymond James analyst Sean McCutcheon characterized the survival outcomes as a “home run” and anticipates widespread adoption. Multiple brokerage firms have described the trial findings as “highly compelling.” Chief Executive Officer Mark Goldsmith stated the medication has “redefined treatment expectations” for this patient population. Revolution Medicines has commenced a rolling NDA submission and intends to pursue regulatory approval globally, including expedited FDA review utilizing a Commissioner’s National Priority Voucher. The FDA has already granted authorization for an expanded access program, enabling qualified patients to access the treatment prior to formal approval. RVMD shares have nearly doubled in value throughout this year and gained more than 9% during May alone. Summit Therapeutics (SMMT) advanced 3.6% to reach $18.17 in premarket activity following positive data for ivonescimab—co-developed with Chinese partner Akeso—which demonstrated a 15% survival improvement versus Tevimbra in direct comparison. Patients diagnosed with advanced squamous non-small cell lung cancer who were administered ivonescimab combined with chemotherapy survived an average of 27.9 months, compared with 23.7 months for those receiving Tevimbra plus chemotherapy. The trial was executed in China. Summit maintains commercialization rights for ivonescimab across the United States, Canada, Europe, and Japan through a licensing agreement valued at up to $5 billion. Some market analysts expressed reservations. Jefferies analyst Faisal Khurshid noted that investors will likely scrutinize whether these outcomes can be reproduced in international trials, especially within U.S. and European populations. SMMT shares have remained relatively unchanged year-to-date.